A global phase II clinical trial of ZM-H1505R
Latest Information Update: 30 Jun 2022
At a glance
- Drugs Canocapavir (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Zhimeng Biopharma
Most Recent Events
- 14 Jun 2022 According to a Zhimeng Biopharma media release, the company plans to initiate this trial in Q3 of 2022.
- 11 May 2022 According to a Zhimeng Biopharma media release, the company plans to kick off this phase II study in June 2022.
- 31 Mar 2022 According to a Zhimeng Biopharma media release, the company expect to begin this trial shortly.